ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

RLMD vs EBS // 10Y YIELD & FRED MACRO BETA

Relmada Therapeutics Inc. (NASDAQ) VS. Emergent BioSolutions Inc. (NYSE) • 15-METRIC TALLY: RLMD 0 — EBS 4
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RLMD VS. EBS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC RLMD EBS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — 56.10% — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 8.90% -43.90 EBS /roic <GO>
EV/EBITDA & P/E Valuation — 6.6x — TIE /valuation <GO>
Free Cash Flow Yield -12.48% — — TIE /fcf-yield <GO>
Operating Margin — 13.50% — TIE /operating-margins <GO>
Net Profit Margin — 7.10% — TIE /net-margins <GO>
Revenue Growth (YoY) — -28.80% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 1.41 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 1/9 8/9 -7.00 EBS /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 52.9 53.0 -0.08 EBS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 6.5x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $366.9M $370.2M -$3.2M EBS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR RLMD REV EBS REV RLMD GROSS % EBS GROSS % RLMD FCF EBS FCF
FY 2025 $0 $742.9M — 56.1% -$45.8M $156.8M
FY 2024 $0 $1.04B — 34.7% -$51.8M $35.8M
FY 2023 — $1.05B — — — -$206.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RLMD // BETA —
EBS // BETA —